Drug intelligence / Profile preview

IOH-005

Development stage: Unknown
Lead developer: ImmuneOncia Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

IOH-005 is a bispecific antibody drug candidate developed by Immuneoncia Therapeutics. It targets both cytokines and LAG3 (lymphocyte activation gene 3 protein), functioning as an inhibitor of these pathways. The drug is designed to modulate immune responses, likely for immuno-oncology applications, by inhibiting cytokine activity and blocking LAG3-mediated immune suppression. As of the latest update, IOH-005 remains in preclinical development with no active clinical trials or approved indications reported[1].

Targets

LAG3 (Lymphocyte activation Gene-3 protein)IL10 (Interleukin-10)

Beyond the preview

Go deeper on IOH-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IOH-005.

Explore the full profile